Mounjaro Gets Broader Approval | Green Bay News

FDA just approved Mounjaro for more adults with type two diabetes at higher risk — and it’s a game-changer. Eli Lilly’s drug slashes major heart events by 8% compared to its older version, Trulicity, and shares the same active ingredient as the weight-loss drug Zepbound. Trials showed equal effectiveness in men and women, though GI side effects are possible. With a potential $1,300 price tag without insurance (or as low as $25 with savings cards), this approval opens new doors for patients — and Eli Lilly isn’t stopping there, already testing next-gen hormone-targeting drugs. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/3f53095d5c405f1e